Further, [89Zr]-Atezolizumab was shown to be tumor-specific when compared to muscle uptake, which revealed a 0.122 ± 0.132 average fraction of PD-L1 tissue (p = 0.0001; Figure 3A). Here, CD274 is linked to neoplasm.